Radiographics 2021 May-Jun;41(3):665-679
From the Department of Radiology (B.R., A.A.L., L.H., H.K.T., S.L.H., Y.G., L.M.), Bernard and Irene Schwartz Center for Biomedical Imaging, Department of Radiology (L.M.), and Center for Advanced Imaging Innovation and Research (CAI2R) (L.M.), New York University Grossman School of Medicine, 160 E 34th St, New York, NY 10016; and Department of Radiology, Beth Israel Deaconess Medical Center, Boston, Mass (L.D.).
Neoadjuvant therapy is increasingly being used to treat early-stage triple-negative and human epidermal growth factor 2-overexpressing breast cancers, as well as locally advanced and inflammatory breast cancers. The rationales for neoadjuvant therapy are to shrink tumor size and potentially decrease the extent of surgery, to serve as an in vivo test of response to therapy, and to reveal prognostic information for the patient. MRI is the most accurate modality to demonstrate response to therapy and to help ensure accurate presurgical planning. Read More